Emerging Non-Traditional Approaches to Combat Antibiotic Resistance

被引:0
作者
Aditya Narayan Konwar
Shabiha Nudrat Hazarika
Pranami Bharadwaj
Debajit Thakur
机构
[1] Microbial Biotechnology Laboratory,Department of Molecular Biology and Biotechnology
[2] Life Sciences Division,undefined
[3] Institute of Advanced Studies in Science and Technology,undefined
[4] Academy of Scientific and Innovative Research (AcSIR),undefined
[5] Cotton University,undefined
来源
Current Microbiology | 2022年 / 79卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
An increasing number of bacterial pathogens are acquiring resistance to the commonly used antibiotics. This has spurred a global threat leading to a resistance era and has penetrated the consciousness of the common people and the clinicians alike. The delay in discovering new antibiotics has exacerbated the resistance problem, forcing researchers to focus on unconventional antimicrobial therapeutics that differ from conventional antibiotics. Alternative therapies have emerged in recent years, including antimicrobial peptides, phage therapy, efflux pump inhibitors, antibodies, and immunomodulatory agents, which have produced impressive results in both laboratory and in clinical trials. Additionally, ultra-narrow-spectrum therapeutics such as CRISPR-Cas system and peptide nucleic acids aided in the development of sequence-specific antimicrobials. Moreover, combinatorial therapies that combine these new approaches have been efficient enough to get approval for clinical use and have accelerated the discovery of novel combination approaches that enhance the performance of already in-use antibiotics. In this review, we provide an overview of these approaches along with studies that focus on the uncharted microbial territories that have been able to deliver some of the important new antibiotics of recent times. It is hoped that the information gathered in this article will provide an update on the current antibiotic resistance threat and encourage profound research.
引用
收藏
相关论文
共 513 条
  • [41] Tomson G(2015)Azithromycin synergizes with cationic antimicrobial peptides to exert bactericidal and therapeutic activity against highly multidrug-resistant gram-negative bacterial pathogens EBioMedicine 6 106-3
  • [42] Woodhouse W(2012)Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium Antimicrob Agents Chemother 8 226-20
  • [43] Ombaka E(2018)Antibiotic hybrids: the next generation of agents and adjuvants against gram-negative pathogens? Clin Microbiol Rev 39 47-e1519
  • [44] Peralta AQ(2017)A tobramycin vector enhances synergy and efficacy of efflux pump inhibitors against multidrug-resistant gram-negative bacteria J Med Chem 18 e3000805-588
  • [45] Qamar FN(2011)Synthetic lethal compound combinations reveal a fundamental connection between wall teichoic acid and peptidoglycan biosyntheses in staphylococcus aureus ACS Chem Biol 9 155-454
  • [46] Mir F(2013)Inhibition of WTA synthesis blocks the cooperative action of PBPS and sensitizes MRSA to β-lactams ACS Chem Biol 21 1313-2
  • [47] Kariuki S(1997)Suppression of β-lactam antibiotic resistance in a methicillin-resistant Staphylococcus aureus through synergic action of early cell wall inhibitors and some other antibiotics J Antimicrob Chemother 224 332-undefined
  • [48] Bhutta ZA(2020)Combining antibiotics with antivirulence compounds can have synergistic effects and reverse selection for antibiotic resistance in Pseudomonas aeruginosa PLoS Biol 12 645485-undefined
  • [49] Coates A(2020)Monoclonal antibodies as an antibacterial approach against bacterial pathogens Antibiotics (Basel) 141 111817-undefined
  • [50] Bergstrom R(2021)Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial Lancet Infect Dis 48 15-undefined